Vancouver, British Columbia — November 5, 2025 — Leads & Copy —PanGenomic Health Inc. (CSE: NARA, FSE:LL3) has announced that it has entered into a non-binding letter of intent with Ayla BioScience, Inc. to enter into an exclusive distribution agreement and a share purchase agreement.
Headquartered in the United States, with operational presence in Colombia and Jamaica, Ayla BioScience is a vertically integrated biomanufacturing company focused on developing and commercializing advanced functional food, nutraceutical, and plant-based bioactive products. The company leverages proprietary solid-state fermentation and dehydration technologies that enhance efficiency and preserve the molecular integrity of bioactive compounds.
The proposed terms of the LOI include PanGenomic Health and Ayla BioScience entering into an exclusive distribution agreement, pursuant to which PanGenomic Health will have the right to market and distribute the Zeotech Products in Canada on an exclusive basis as part of a personalized medicine solution for at least two years, and PanGenomic purchasing shares in Ayla BioScience for a maximum purchase price of C$150,000, payable in a combination of cash and shares of PanGenomic Health.
The proposed transaction is subject to the negotiation and execution of final terms, definitive documentation, the performance of any closing conditions, and approval by the Canadian Securities Exchange.
PanGenomic Health has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. Ayla BioScience develops and markets a portfolio of functional foods, nutraceuticals, and plant-derived bioactive products under its ZeoMycel™ and Zeophytoz™ brands.
For more information, please contact:
Fairfax Partners Inc.
Daniel Southan-Dwyer, President
+1 604 305 5369
fair@fairfax.partners
Source: PanGenomic Health Inc.
